Aurinia Pharmaceuticals Inc.

AUPH - CIK 0001600620

Market cap$2.01 B

Rank#2095

SEC filings595

Aurinia Pharmaceuticals Inc. trades as AUPH and has a market capitalization of $2.01 B, making it the #2095 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $283.06M, up 20.4% from the prior year and net income of $287.20M. This page tracks Aurinia Pharmaceuticals Inc. through 595 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$283.06MFY 2025

Net income (latest FY)$287.20MFY 2025

Operating cash flow (latest FY)$135.66MFY 2025

Total assets (latest FY)$751.59MFY 2025

Net margin101.5%latest FY

Financial performance

Over the last 7 fiscal years Aurinia Pharmaceuticals Inc.'s revenue grew from $463.00K to $283.06M, a compound annual growth rate of 150.1%. Net profit margin expanded from -11464.1% to 101.5% over the same period - every figure below comes from the company's audited annual filings.

AUPH annual revenueView details

Key statistics

Market cap: $2.01 B
Share price (derived)market cap / shares outstanding: $15.63
P/E ratio (trailing FY): 7.0
EPS (diluted)FY 2025: $2.07
Shares outstandingas of 2026-05-06: 0.13B
Total equityas of 2026-03-31: $567.63M
Return on equity: 50.6%
Cash & equivalentsas of 2026-03-31: $40.75M

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-20
Insider trade	4	2026-05-20
Insider trade	4	2026-05-20
Insider sale notice	144	2026-05-11
Insider sale notice	144	2026-05-11
Insider sale notice	144	2026-05-11
Major company event	8-K	2026-05-11
SC TO-T/A	-	2026-05-11

Browse the full filing history (595 filings)

Recent press releases

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress2026-03-31
About Aurinia Management Team Board of Directors Responsibility
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right2026-03-30
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right | Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Announces Management Transition | Aurinia Pharmaceuticals Inc. (AUPH)2026-03-23
Aurinia Announces Management Transition | Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress2025-12-31
About Aurinia Management Team Board of Directors Responsibility
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 20262025-12-31
About Aurinia Management Team Board of Directors Responsibility

Similar companies

The largest companies sharing Aurinia Pharmaceuticals Inc.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T AUPH vs LLY

JNJJohnson & Johnson$573.98 B AUPH vs JNJ

ABBVAbbVie Inc.$399.47 B AUPH vs ABBV

MRKMerck & Co., Inc.$293.16 B AUPH vs MRK

AZNAstraZeneca PLC$286.27 B AUPH vs AZN

Frequently asked questions

What is Aurinia Pharmaceuticals Inc.'s market cap?

Aurinia Pharmaceuticals Inc. (AUPH) has a market capitalization of $2.01 B as of 2026-06-10, ranking #2095 among US-listed companies.

How much revenue does Aurinia Pharmaceuticals Inc. make?

Aurinia Pharmaceuticals Inc. reported revenue of $283.06M for fiscal year 2025, an increase of 20.4% year over year.

Is Aurinia Pharmaceuticals Inc. profitable?

Yes. Aurinia Pharmaceuticals Inc. reported net income of $287.20M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.